Jeffrey L. Edelman
22Patents
4h-index
17Co-inventors
56Inventor score
Filing activity: Apr 30, 2004 → Sep 10, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8512738B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 58 | Active |
| US7771742B2 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods | Emerging Cross-Sectional Technologies | 37 | Active |
| US8062657B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | Emerging Cross-Sectional Technologies | 26 | Active |
| US8968766B2 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods | Emerging Cross-Sectional Technologies | 19 | Active |
| US7749530B2 | Kinase inhibitors | Chemistry; Metallurgy | 4 | Active |
| US9233070B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 3 | Active |
| US8906892B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 3 | Active |
| US8840872B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | Emerging Cross-Sectional Technologies | 3 | Active |
| US8865691B2 | Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 3 | Active |
| US9433631B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 3 | Active |
| US9259429B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | Emerging Cross-Sectional Technologies | 2 | Active |
| US8455656B2 | Kinase inhibitors | Human Necessities | 2 | Active |
| US10076492B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 2 | Active |
| US8143410B2 | Kinase inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US9717743B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 1 | Active |
| US10881608B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 0 | Active |
| US10188665B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | Emerging Cross-Sectional Technologies | 0 | Active |
| US10493082B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 0 | Active |
| US8969583B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9820995B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | Emerging Cross-Sectional Technologies | 0 | Active |
| US10188667B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Human Necessities | 0 | Active |
| US8383825B2 | Kinase inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.